Prostate-specific antigen screening and 15-year prostate cancer mortality: A secondary analysis of the CAP randomised clinical trial – UROONCO Prostate Cancer
A single invitation for PSA screening compared with standard practice without routine screening reduced prostate cancer deaths at a median follow-up of 15 years.